New Alzheimer’s drug slows cognitive decline by 35%, trial results show

Lilly, the maker of donanemab, is applying for approval in the US next month and other countries shortly after. Photograph: Darron Cummings/AP

A new Alzheimer’s drug slowed cognitive decline by 35%, according to late-stage trial results, raising the prospect of a second effective treatment for the disease.

Donanemab met all goals of the trial and slowed progression of the condition by 35% to 36% compared with a placebo in 1,182 people with early-stage Alzheimer’s, the drugmaker Lilly said.